A medical doctor, Mwango is an expert in development of analgesic and addiction therapies and post-approval activities (pharmacovigilance, risk management, Phase IV studies). Before joining Parexel in 2018, she spent 16 years with the Food and Drug Administration (FDA), most recently as associate director for safety. She has deep knowledge of review and development of small molecules and biologics, over-the-counter products, and generics. Mwango is board-certified in preventive medicine and public health. She gained her academic training at Johns Hopkins University School of Medicine and the Columbia Mailman School of Public Health. As senior vice president, global head of regulatory strategy at Parexel, Mwango builds and leads multidisciplinary teams to conceptualize and implement projects and programs to advance drug safety science and policy.
This roundtable will discuss key considerations for building integrated evidence at the earliest stages of development to satisfy the needs of multiple stakeholders.
Sponsored by Parexel.